Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- 31 October 2010
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 37 (5), 508-516
- https://doi.org/10.1053/j.seminoncol.2010.09.008
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in MicePLOS ONE, 2010
- Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against MelanomaPublished by The American Association of Immunologists ,2010
- CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cellsBlood, 2010
- Combination Therapy with Cisplatin and Anti–4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced NephrotoxicityCancer Research, 2008
- Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependentJCI Insight, 2007
- Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces AutoimmunityCancer Research, 2006
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006
- Involvement of tumor necrosis factor receptor superfamily (TNFRSF) members in the pathogenesis of inflammatory diseasesExperimental & Molecular Medicine, 2003
- CD137 Expression in Tumor Vessel WallsAmerican Journal of Clinical Pathology, 2001